Top
image credit: Adobe Stock

FDA’s Office of New Drugs Highlights New Research Projects for Growth

April 18, 2023

Category:

In 2018, FDA’s Center for Drug Evaluation and Research’s (CDER’s) Office of New Drugs (OND) developed a research program to centralize and enhance its regulatory science research activities. In more recent years, the OND Research Program (OND-RP) published its first two fiscal year annual reports, and there are important projects that are looking to help improve research outcomes for patient populations.

Read More on Biopharm International